Indiva Competitors

Indiva (CVE:NDVA) and WeedMD (CVE:WMD) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability.

Analyst Ratings

This is a breakdown of current recommendations for Indiva and WeedMD, as reported by MarketBeat.

Indiva presently has a consensus target price of C$0.63, indicating a potential upside of 51.81%. WeedMD has a consensus target price of C$0.58, indicating a potential upside of 88.17%. Given WeedMD's higher probable upside, analysts plainly believe WeedMD is more favorable than Indiva.

Profitability

This table compares Indiva and WeedMD's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Indiva and WeedMD's top-line revenue, earnings per share and valuation.

Indiva has higher earnings, but lower revenue than WeedMD. WeedMD is trading at a lower price-to-earnings ratio than Indiva, indicating that it is currently the more affordable of the two stocks.

Summary

Indiva beats WeedMD on 5 of the 8 factors compared between the two stocks.

Indiva (CVE:NDVA) and Delta 9 Cannabis (CVE:NINE) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability.

Analyst Ratings

This is a breakdown of current recommendations for Indiva and Delta 9 Cannabis, as reported by MarketBeat.

Indiva presently has a consensus target price of C$0.63, indicating a potential upside of 51.81%. Given Indiva's higher probable upside, equities research analysts plainly believe Indiva is more favorable than Delta 9 Cannabis.

Profitability

This table compares Indiva and Delta 9 Cannabis' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Indiva and Delta 9 Cannabis' top-line revenue, earnings per share and valuation.

Delta 9 Cannabis has higher revenue and earnings than Indiva. Indiva is trading at a lower price-to-earnings ratio than Delta 9 Cannabis, indicating that it is currently the more affordable of the two stocks.

Summary

Delta 9 Cannabis beats Indiva on 4 of the 7 factors compared between the two stocks.

Indiva (CVE:NDVA) and Acerus Pharmaceuticals (TSE:ASP) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability.

Earnings & Valuation

This table compares Indiva and Acerus Pharmaceuticals' top-line revenue, earnings per share and valuation.

Indiva has higher revenue and earnings than Acerus Pharmaceuticals. Indiva is trading at a lower price-to-earnings ratio than Acerus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current recommendations for Indiva and Acerus Pharmaceuticals, as reported by MarketBeat.

Indiva presently has a consensus target price of C$0.63, indicating a potential upside of 51.81%. Given Indiva's higher probable upside, equities research analysts plainly believe Indiva is more favorable than Acerus Pharmaceuticals.

Profitability

This table compares Indiva and Acerus Pharmaceuticals' net margins, return on equity and return on assets.

Summary

Indiva beats Acerus Pharmaceuticals on 4 of the 7 factors compared between the two stocks.

The Flowr (CVE:FLWR) and Indiva (CVE:NDVA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, profitability, valuation, analyst recommendations, risk and earnings.

Valuation and Earnings

This table compares The Flowr and Indiva's gross revenue, earnings per share (EPS) and valuation.

Indiva has higher revenue and earnings than The Flowr. Indiva is trading at a lower price-to-earnings ratio than The Flowr, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations and price targets for The Flowr and Indiva, as provided by MarketBeat.com.

The Flowr presently has a consensus price target of C$0.88, indicating a potential upside of 227.16%. Indiva has a consensus price target of C$0.63, indicating a potential upside of 51.81%. Given The Flowr's higher probable upside, equities analysts plainly believe The Flowr is more favorable than Indiva.

Profitability

This table compares The Flowr and Indiva's net margins, return on equity and return on assets.

Summary

Indiva beats The Flowr on 4 of the 7 factors compared between the two stocks.

BioSyent (CVE:RX) and Indiva (CVE:NDVA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, profitability, valuation, analyst recommendations, risk and earnings.

Valuation and Earnings

This table compares BioSyent and Indiva's gross revenue, earnings per share (EPS) and valuation.

BioSyent has higher revenue and earnings than Indiva. Indiva is trading at a lower price-to-earnings ratio than BioSyent, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations and price targets for BioSyent and Indiva, as provided by MarketBeat.com.

BioSyent presently has a consensus price target of C$7.00, indicating a potential downside of 9.68%. Indiva has a consensus price target of C$0.63, indicating a potential upside of 51.81%. Given Indiva's stronger consensus rating and higher probable upside, analysts plainly believe Indiva is more favorable than BioSyent.

Profitability

This table compares BioSyent and Indiva's net margins, return on equity and return on assets.

Medexus Pharmaceuticals (CVE:MDP) and Indiva (CVE:NDVA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, profitability, valuation, analyst recommendations, risk and earnings.

Valuation and Earnings

This table compares Medexus Pharmaceuticals and Indiva's gross revenue, earnings per share (EPS) and valuation.

Indiva has lower revenue, but higher earnings than Medexus Pharmaceuticals. Medexus Pharmaceuticals is trading at a lower price-to-earnings ratio than Indiva, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Medexus Pharmaceuticals and Indiva, as provided by MarketBeat.com.

Indiva has a consensus price target of C$0.63, indicating a potential upside of 51.81%. Given Indiva's higher probable upside, analysts plainly believe Indiva is more favorable than Medexus Pharmaceuticals.

Profitability

This table compares Medexus Pharmaceuticals and Indiva's net margins, return on equity and return on assets.

Summary

Indiva beats Medexus Pharmaceuticals on 5 of the 7 factors compared between the two stocks.